Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Summary of Goodwill

As of December 31, 2023, the goodwill associated with the AxoBio Acquisition, as shown below, is classified as a component of assets available for sale in the accompanying consolidated balance sheets.

Balance as of January 1, 2023	$	—
AxoBio Acquisition		19,188,278
Balance as of December 31, 2023	$	19,188,278

Summary of Securities that were Excluded from the Diluted Per Share

Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the periods ended December 31, 2023 and 2022, consist of the following (in common stock equivalents):

	December 31,
	2023		2022
Series A Preferred Stock (if converted)		4,243,000		—
Stock Options		1,689,765		2,235,313
Public Warrants		4,638,454		3,870,524
Series A Preferred Stock (if converted)		—		2,010,728
Series B Preferred Stock (if converted)		—		2,817,886
Series C-1 Preferred Stock (if converted)		—		89,264
Series C-2 Preferred Stock (if converted)		—		5,857,512
Preferred Stock Warrants		—		164,894
Convertible Notes (if converted)		—		777,062
Total		10,571,219		17,823,183

Schedule of Other Financial Assets and Liabilities Recorded in Balance Sheet at Fair Value

Other financial assets and liabilities as of December 31, 2023 and 2022 are categorized based on a hierarchy of inputs as follows:

	December 31, 2023				December 31, 2022				Fair Value
	Carrying		Estimated		Carrying		Estimated		Input
	Value		Fair Value		Value		Fair Value		Hierarchy
Forward purchase agreement	$	5,700,451	$	5,700,451	$	—	$	—		Level 3
SBA Loan		1,505,070		1,498,000		—		—		Level 2
Derivative liabilities		—		—		826,980		826,980		Level 3

Schedule of Changes in Fair Value of Level 3 Financial Assets and Liabilities

Changes in the fair value of Level 3 financial assets and liabilities for the year ended December 31, 2023 are as follows:

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Forward Purchase Agreement			Derivative Liabilities			Earnout Liabilities
Balance, beginning of year	$	—		$	826,980		$	—
Initial recognition		15,968,581			—			13,482,292
Change in fair value		(10,268,130	)		(826,980	)		38,093
Balance, end of period	$	5,700,451		$	—		$	13,520,385

Schedule of Fair Value of the Overallotment Liability

The fair value of the embedded derivatives in the convertible notes as of December 31, 2022 was valued using a Monte-Carlo model and was based upon the following management assumptions:

	December 31, 2022
Stock price	$	2.60
Expected term (years)		0.04
Volatility		55.1	%
Risk-free interest rate		4.38	%
Probability of Qualified Financing or IPO		50.00	%
Probability of a Change in Control Event		10.00	%